Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM0504 in non-diabetic overweight or obese adults
NCT06714955Phase 1Completed
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BGM0504 in obesity (3 arms), sponsored by BrightGene Bio-Medical Technology. Primary endpoint: Adverse Events at 10 weeks. Started Oct 2024; status: completed.
02
Drugs
BGM0504
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06714955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714955.